VIQ Solutions Inc. (Nasdaq: VQS) has announced a strategic partnership with Justice AV Solutions (JAVS), a renowned global provider of court recording and AV services. This collaboration aims to revolutionize the legal profession by introducing AI-generated draft transcripts of courtroom proceedings.

Through this partnership, legal professionals can expect an expedited transcript of courtroom proceedings, thanks to the integration of VIQ Solutions' advanced technology with JAVS' expertise in court recording services. The use of artificial intelligence enables the generation of accurate and searchable draft transcripts, ultimately facilitating faster decision-making processes within the legal system.

In response to this announcement, $VQS is trading at $0.42 in pre-market, experiencing a significant increase of $0.15 (60.32%).

In other news, Altamira Therapeutics Ltd. (Nasdaq: CYTO) has received favorable news from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application for AM-125 (betahistine nasal spray). 

The FDA has completed its safety review and concluded that Altamira's proposed Phase 2 clinical trial with AM-125 for the treatment of posterior canal benign paroxysmal positional vertigo (BPPV) may proceed. 

In  pre-market, $CYTO is trading at $0.86, up $0.05 (+6.17%).

Furthermore, The Kroger Co. (NYSE: KR) reported first-quarter 2023 adjusted earnings per share (EPS) of $1.51, surpassing the consensus estimate of $1.46. 

Building on this success, Kroger is raising its guidance for Adjusted Free Cash Flow for the full year 2023, projecting a range of $2.5 to $2.7 billion. Additionally, the company reaffirms its expectations for adjusted net earnings per diluted share in the range of $4.45 to $4.60, aligning with the consensus estimate of $4.50 for the period.

However, the market response to Kroger's earnings report has been mixed, as $KR is trading at $45.21 in pre-market, down $2.00 (-4.24%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)